Company News

Oct 20, 2024 | BALTIMORE – Complete Omics Inc., a trailblazer in clinical proteomics and multi-omics molecular diagnostics, is proud to announce its recent achievement of CLIA and CAP certifications, along with enrollment in the Medicare system. These accomplishments underscore Complete Omics’ unwavering commitment to providing top-tier diagnostic solutions, grounded in excellence and reliability, and advancing patient care through accessible, state-of-the-art clinical proteomics testing services.

The CLIA (Clinical Laboratory Improvement Amendments) certification sets a federally mandated standard for laboratory quality, accuracy, and compliance. Achieving this certification confirms Complete Omics’ ability to deliver consistent, high-quality diagnostic results that healthcare providers and patients can trust.

Adding to this achievement, the CAP (College of American Pathologists) certification is another hallmark of Complete Omics’ dedication to excellence. Recognized as the gold standard in laboratory quality assurance, CAP certification involves rigorous inspections and assessments, ensuring that our laboratory adheres to the highest standards in pathology and laboratory medicine. Together, these certifications validate our ongoing commitment to clinical integrity, reliability, and patient safety.

Enrollment in the Medicare system further broadens access to Complete Omics’ advanced diagnostics, making our cutting-edge proteomics-based testing solutions available to Medicare beneficiaries. With this inclusion, Complete Omics is poised to bring critical insights for early disease detection and personalized treatment to a larger population, reinforcing its mission to make precision diagnostics a standard in modern healthcare.

“Our CLIA and CAP certifications, along with Medicare enrollment, mark significant milestones for Complete Omics as we expand our reach and impact in the clinical diagnostics field,” said Qing Wang, Founder and CEO of Complete Omics Inc. “We are dedicated to providing healthcare professionals and patients with reliable, high-quality diagnostic services that empower precise healthcare decisions and foster improved patient outcomes.”

Complete Omics Inc. remains committed to innovation and quality in clinical proteomics and multi-omics blood tests, setting new benchmarks in diagnostic technology and accessibility.

May 12, 2024 | BALTIMORE –  Complete Omics is thrilled to announce that our Valid-NEO^® platform’s “Method and System for Neoantigen Analysis” has been granted a U.S. patent after a rigorous three-year review by the USPTO. This breakthrough makes Valid-NEO^® the only patented method in the U.S. capable of directly quantifying neoantigens on cell surfaces. This milestone underscores the platform’s significant technical value, setting it apart in the neoantigen detection field.

Valid-NEO^® has revolutionized the market with its ability to overcome traditional challenges in cancer-related gene mutation analysis. By directly and accurately detecting neoantigens with high sensitivity and specificity, Valid-NEO^® allows for absolute quantification and precise analysis at the single-cell level, requiring minimal sample amounts. This makes it a game-changer in personalized medicine and drug development, offering unparalleled accuracy in identifying neoantigen sequences and their immunogenicity.

In practice, Valid-NEO^® supports both innovative drug development and companion diagnostics, helping pharmaceutical companies identify patients suitable for clinical trials and aiding in personalized treatment planning. Unlike traditional gene sequencing combined with AI algorithms, Valid-NEO^® offers superior sensitivity by directly reading data from cell surfaces, making it a core technology in identifying tumor neoantigen targets and enhancing cancer immunotherapy.

We are immensely proud of this achievement and its implications for the future of cancer treatment. Valid-NEO^® not only advances neoantigen detection but also deepens the application of personalized medicine in oncology. We believe this patented technology will drive the development of new drugs and therapies targeting tumor neoantigens, accelerating the realization of more universal personalized cancer immunotherapy solutions.

For detailed case studies on Valid-NEO^® applications, please refer to our publications:

1. “Targeting a neoantigen derived from a common TP53 mutation,” Science, 2021.
2. “Bispecific antibodies targeting mutant RAS neoantigens,” Science Immunology, 2021.
3. “Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy,” Science Advances, 2022.